Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Cancer Vaccine 2.0
share announcement

Cancer Vaccine 2.0

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".

Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 6105

Special Issue Editor

Dr. So Young Yoo

E-Mail Website
Guest Editor
BIO-IT Foundry Technology Institute, Pusan National University, Busan, Republic of Korea
Interests: cancer immunotherapy; virotherapy; regenerative therapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Vaccines have saved millions of people from infectious diseases. Despite advances in immunology and medicine, developing vaccines against cancers is still a challenge for researchers. Recent studies have shown some remarkable steps toward successful development. Vaccines are used to induce antitumor immunity through specific tumor-associated antigens. Cancer cells also express normal cells’ antigens, which limits therapeutic vaccine development. Targeting tumor-associated antigens and neoantigens on cancer cells is widely used to stimulate effective antitumor immunity in therapeutic vaccine approaches. In addition, various adjuvants have been used to enhance antitumor immunity with these targeting approaches. The tumor microenvironment comprises various immune cells and suppresses tumor antigen expression. In order to target the tumor microenvironment, combined therapeutic approaches using oncolytic viruses, immune checkpoint inhibitors, and adoptive T-cells therapy have been widely employed. This issue will especially focus on cancer vaccine development. Therefore, we welcome research articles as well as review articles, which would not only provide immense knowledge on these topics but also lead to new directions in cancer vaccine research.

Dr. So Young Yoo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer immunotherapy
  • therapeutic vaccine
  • tumor-associated antigens
  • neoantigens
  • adjuvant
  • tumor microenviroment
  • oncolytic viruses
  • immune checkpoint inhibitors

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

6 pages, 536 KiB  
Communication
Optimization of Whole Tumor Cell Vaccines by Interaction with Phagocytic Receptors
by Mladen Korbelik
Vaccines 2021, 9(8), 904; https://doi.org/10.3390/vaccines9080904 - 14 Aug 2021
Cited by 6 | Viewed by 1846
Abstract
The principal event in the function of whole-cell cancer vaccines is the ingestion of vaccine-delivered tumor antigen-containing material, which is performed by the patient’s antigen-presenting cells (APCs) through the employment of their phagocytic receptors. The goal of the present study was to identify [...] Read more.
The principal event in the function of whole-cell cancer vaccines is the ingestion of vaccine-delivered tumor antigen-containing material, which is performed by the patient’s antigen-presenting cells (APCs) through the employment of their phagocytic receptors. The goal of the present study was to identify the phagocytic receptors critical for the therapeutic efficacy of whole-cell cancer vaccines. The model of photodynamic therapy (PDT)-generated vaccines based on mouse SCCVII tumors was utilized, with in vitro expanded SCCVII cells treated by PDT serving as the vaccine material used for treating mice bearing established SCCVII tumors. The therapeutic impact, monitored as delayed progression of vaccinated tumors, was almost completely eliminated when antibodies specifically blocking the activity of LOX-1 scavenger receptor were administered to mice 30 min before vaccination. Similar, but much less pronounced, impacts were found with antibodies neutralizing the activity of CR3/CR4 receptors recognizing complement-opsonized vaccine cells, and with those blocking activating Fcγ receptors that recognized IgG antibody-based opsonins. A strikingly contrary action, a greatly enhanced tumor control by the vaccine, was found by blocking immune inhibitory receptor, FcγRIIB. The reported findings establish, therefore, an attractive strategy that can be effectively exploited for potent therapeutic enhancement of PDT-generated (and probably other) whole-cell tumor vaccines. Full article
(This article belongs to the Special Issue Cancer Vaccine 2.0)
►▼ Show Figures

Figure 1

Review

Jump to: Research

16 pages, 1539 KiB  
Review
Oncolytic Vaccinia Virus in Lung Cancer Vaccines
by Cao-Sang Truong and So Young Yoo
Vaccines 2022, 10(2), 240; https://doi.org/10.3390/vaccines10020240 - 4 Feb 2022
Cited by 11 | Viewed by 3670
Abstract
Therapeutic cancer vaccines represent a promising therapeutic modality via the induction of long-term immune response and reduction in adverse effects by specifically targeting tumor-associated antigens. Oncolytic virus, especially vaccinia virus (VV) is a promising cancer treatment option for effective cancer immunotherapy and thus [...] Read more.
Therapeutic cancer vaccines represent a promising therapeutic modality via the induction of long-term immune response and reduction in adverse effects by specifically targeting tumor-associated antigens. Oncolytic virus, especially vaccinia virus (VV) is a promising cancer treatment option for effective cancer immunotherapy and thus can also be utilized in cancer vaccines. Non-small cell lung cancer (NSCLC) is likely to respond to immunotherapy, such as immune checkpoint inhibitors or cancer vaccines, since it has a high tumor mutational burden. In this review, we will summarize recent applications of VV in lung cancer treatment and discuss the potential and direction of VV-based therapeutic vaccines. Full article
(This article belongs to the Special Issue Cancer Vaccine 2.0)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop